Phase 3 Readout
NBIX: Phase 3 Topline: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and To
June 1, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- June 1, 2026
- Company
- NEUROCRINE BIOSCIENCES INC (NBIX)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and To
- Indication
- Dyskinesia; Cerebral Palsy